EP08.02-067 Concurrent Aumolertinib Plus Icotinib for First-Line Treatment of EGFR Mutated Non-small Cell Lung Cancer with Brain Metastases

Brain metastases are associated with significant morbidity and are found in up to 50% of patients with advanced non-small cell lung cancer (NSCLC), and seriously affect the prognosis of lung cancer patients. Currently, brain metastasis of epidermal growth factor receptor (EGFR) sensitive mutations is a hot and difficult point in targeted era of NSCLC treatment, meanwhile it is also the central issue of controversy in the field of lung cancer treatment. Additionally, EGFR tyrosine kinase inhibitors (EGFR-TKIs) have been recommended as standard therapy for asymptomatic NSCLC patients with EGFR mutations with brain metastases.